Risk Stratification and Benefits With Cardiac Resynchronization Therapy (CRT) (BENEFIT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00996086 |
Recruitment Status :
Completed
First Posted : October 16, 2009
Last Update Posted : February 4, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Heart Failure Ventricular Arrhythmias | Device: CRT device implant |
The purpose of the study is two-fold. First, to determine if an algorithm can be developed based on pre-implant clinical variables to predict response to CRT-D therapy. Second, the study aims to determine in patients implanted with CRT-D if the combined use of cTnT and BNP can further predict and risk-stratify HF improvement and all-cause mortality. Additionally, novel biochemical markers defining cardiac mortality in high risk patients detected by plasma proteomic analysis in the CRT-D patients will be evaluated.
This study represents a combination of previous CRT studies that evaluated these variables independently. Data from this study will be pooled with data from previous studies to build a more complete picture of CRT therapy.
Study Type : | Observational |
Actual Enrollment : | 154 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Risk Stratification and Benefits With Cardiac Resynchronization Therapy |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | September 2012 |
Actual Study Completion Date : | September 2012 |
Group/Cohort | Intervention/treatment |
---|---|
CRT device-recipients |
Device: CRT device implant
CRT device-recipients |
- Change in 6-minute hall walk distance between baseline and subsequent follow-up [ Time Frame: 12 months ]
- Composite endpoint a. 6-minute hall walk distance b. NYHA Classification c. Quality of Life (Minnesota Living with Heart Failure, DASS, SF-36) [ Time Frame: 12 months ]
- The occurrence of either death (all-cause) or first HF hospitalization. [ Time Frame: 12 months ]
- Quality of Life [ Time Frame: 12 months ]
- Change in echocardiographic variables including: a. Ejection Fraction b. Wall motion score c. Increase in TD velocity d. Yu index [ Time Frame: 12 months ]
- Cause-specific mortality [ Time Frame: 12 months ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Meets current clinical indications for CRT-D therapy
- Patient is 18 years old or older
- Ability to independently comprehend and complete all QOL questionnaires
- Patient has the ability to perform the 6-minute Hall Walk Test (6-MHW) with the only limiting factor being fatigue or shortness-of-breath
- Ability to provide informed consent for a study and be willing and able to comply with the prescribed follow-up
Exclusion Criteria:
- Inability to successfully implant an intravascular lead and CRT-D device. (i.e. exclude epicardial leads) within 30 days of initial procedure.
- Myocardial infarction in the last 3 weeks
- Unstable angina in the last 3 weeks
- Status 1 classification for cardiac transplantation
- Currently participating in a clinical trial that includes an active treatment arm
- Life expectancy of less than 12 months.
- Recent (within 1 week) administration of Nesiritide™ or inotropes
- Patients in whom revascularization is expected
- Patient is pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00996086
United States, New York | |
Touro College | |
New York, New York, United States, 10010 | |
United States, Pennsylvania | |
Veterans' Adminstration Pittsburgh Healthcare System | |
Pittsburgh, Pennsylvania, United States, 15240 |
Principal Investigator: | Alan Kadish, M.D. | Northwestern University | |
Principal Investigator: | Alaa Shalaby, M.D. | VA Pittsburgh Healthcare System |
Responsible Party: | Abbott Medical Devices |
ClinicalTrials.gov Identifier: | NCT00996086 |
Other Study ID Numbers: |
CRD 480 |
First Posted: | October 16, 2009 Key Record Dates |
Last Update Posted: | February 4, 2019 |
Last Verified: | February 2019 |
Heart Failure Heart Diseases Cardiovascular Diseases |